MedPath

Superior Vena Cava Collapsibility Index for Predicting Fluid Responsiveness During High-risk Non-cardiac Surgery

Not Applicable
Recruiting
Conditions
Fluid Responsiveness
Transesophageal Echocardiography
Surgery
Registration Number
NCT06188039
Lead Sponsor
Uniwersytecki Szpital Kliniczny w Opolu
Brief Summary

The goal of this prospective study is to validate the superior vena cava collapsibility index (SVC-CI) as a predictor of fluid responsiveness during laparotomy and open aortic surgery. The SVC-CI and patients' response to fluid will be assessed based on transesophageal echocardiography.

The study has three arms, in order to validate SVC-CI under the conditions of laparotomy, aortic cross clamping and high PEEP levels. One of the study arms will be an active comparator arm.

The data obtained from this study may help physicians guide intraoperative fluid therapy in a more efficient manner, in order to decrease perioperative mortality.

Detailed Description

Patients undergoing high-risk non-cardiac surgery, including acute laparotomies and open aortic surgery, are at high risk of postoperative complications and adverse cardiovascular events. Perioperative fluid therapy is a factor which is strongly associated with postoperative outcomes. To avoid both hypovolemia and excessive fluid administration a strategy of goal-directed fluid therapy (GDFT) has been coined. Traditionally in the setting of operating rooms GDFT relied on stroke-volume variation (SVV) measured by hemodynamic monitors, based on uncalibrated pulse contour cardiac output analysis (uAPCO). However in the described cohort of patients uAPCO methods show a significantly increased measurement error, which is mainly attributed to dynamic changes in peripheral vascular tone. Furthermore, frequent occurrence of arhytmias in those patients limits the use of SVV and all other dynamic indices of fluid responsiveness based on those methods. Superior vena cava collapsibility index (SVC-CI) is a parameter which is devoid of the above mentioned limitations. It relies on respiratory variation of superior vena cava during the respiratory cycle and is therefore reliable in patients with irregular heart rhytm and seems independent from changing afterload conditions.

The main purpose of this study is to validate SVC-CI in patients undergoing controlled mechanical ventilation during laparotomies and during open aortic surgery, with focus on elevated PEEP levels and aortic cross-clamping.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Signed ICF (informed consent form)
  • Age > 18 years old Eligibility criteria for each arm (additionally to mandatory criteria)
  • Arm 1 - Patients undergoing open aortic surgery
  • Arm 2 - Patients undergoing laparotomy
  • Arm 3 - Patients undergoing laparotomy with sinus rhytm
Exclusion Criteria
  1. Patients who are deemed to be at risk of harm due to excessive fluid administration:

    • End-stage renal disease (eGFR <15ml/kg/min)
    • Decompensated heart failure
    • Respiratory failure prior to surgery
    • Other cases where the risk of harm from fluid overload is assessed to be significant by the investigator
  2. Medical contraindication to the use of transesophageal echocardiography:

    • Active ulcerative gastritis or bleeding from upper gastrointestinal tract
    • Past history of esophageal or gastric surgery
    • Esophageal varices or other esophageal disease (stricture, Barret's disease, perforation in the past, achalasia)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Fluid responsivenessDirectly after infusing fluid bolus.

Fluid responsiveness was defined as an increase of 10% or more of cardiac output (CO) following an administered 250ml fluid bolus. Changes in CO will be estimated using changes in left ventricle outflow tract velocity time integral (LVOT-VTI) assessed by transesophageal echocardiography to avoid errors associated with measuring LVOT area, which is necessary to calculate CO.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Opole University Hospital

🇵🇱

Opole, Poland

Opole University Hospital
🇵🇱Opole, Poland
Tomasz Królicki, MD PhD
Principal Investigator
Tomasz Czarnik, MD PhD
Sub Investigator
Ryszard Gawda, MD PhD
Sub Investigator
Mateusz Stanisz, MD
Sub Investigator
Maciej Molsa, MD
Sub Investigator
Maciej Piwoda, MD
Sub Investigator
Marek Piętka, MD
Sub Investigator
Jakub Jedrzejczyk, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.